{"id":"NCT03029234","sponsor":"Amgen","briefTitle":"Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma","officialTitle":"An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-31","primaryCompletion":"2018-11-05","completion":"2021-06-04","firstPosted":"2017-01-24","resultsPosted":"2019-11-21","lastUpdate":"2022-05-25"},"enrollment":126,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsed and Refractory Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Dexamethasone","otherNames":[]},{"type":"DRUG","name":"Carfilzomib","otherNames":["Kyprolis"]}],"arms":[{"label":"Carfilzomib with Dexamethasone","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.","primaryOutcome":{"measure":"Overall Response Rate (ORR) After at Least 6 Cycles of Treatment Assessed by the Independent Review Committee","timeFrame":"Response was assessed every 28 days until disease progression; ORR was analyzed after all participants received at least 6 cycles or discontinued treatment; the data cut-off date was 5 November 2018; median follow-up time for progression was 8.9 months.","effectByArm":[{"arm":"Carfilzomib With Dexamethasone","deltaMin":35.8,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["China"]},"refs":{"pmids":["33389656"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":68,"n":123},"commonTop":["Anaemia","Upper respiratory tract infection","Platelet count decreased","White blood cell count decreased","Hypertension"]}}